Emerging Treatments: Hematological Cancers

Over the past few decades, application of immunotherapy in cancer has gone from concept to successful therapy. In particular, manipulation and modification of T-cells has led to exciting results in treating heme malignancies such as acute and chronic leukemia, lymphomas, and multiple myeloma. In particular, CAR-T therapies and bispecific antibodies have shown success in treating several such cancers and have moved from drugs of last resort to earlier lines of therapy. This panel will discuss the progress that has resulted from introduction of highly targeted bispecific antibodies, as well as cell and gene hybrid therapies such as CAR-T, and will address challenges for future developments.